Recruiting
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
NCT04775745
- Conditions
- Blood Protein Disorders, CLL/SLL, Cardiovascular Diseases, +28 more
- Locations
-
- Duke Univerisity Durham, North Carolina, United States
- University of Cincinnati Cincinnati, Ohio, United States
- Ohio State University Columbus, Ohio, United States
- Huntsman Cancer Institute, University of Utah Salt Lake City, Utah, United States